Onco-Innovations Ltd. is a Canadian biotech company, which engages in cancer research and treatment, specializing in oncology. The company is headquartered in Calgary, Alberta. The company went IPO on 2024-11-27. The firm holds an exclusive worldwide license to patented technology that targets solid tumors. The firm is engaged in developing and commercializing treatments for various types of cancer. Its solution focuses on targeting cancer cells, effectively eliminating them and preventing their regrowth. Its licensed technology focuses on Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitors. Its SynoGraph platform merges genomic, proteomic, and multimodal datasets to uncover deep insights into disease mechanisms, potentially enabling more personalized and effective treatment strategies.
Follow-Up Questions
¿Quién es el CEO de Onco-Innovations Ltd?
Mr. Thomas Oshaughnessy es el Chief Executive Officer de Onco-Innovations Ltd, se unió a la empresa desde 2024.
¿Qué tal es el rendimiento del precio de la acción ONNVF?
El precio actual de ONNVF es de $0, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Onco-Innovations Ltd?
Onco-Innovations Ltd pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Onco-Innovations Ltd?
La capitalización bursátil actual de Onco-Innovations Ltd es $NaN
